Since 2018, eight novel-mechanism calcitonin gene-related peptide (CGRP) antagonists have been FDA-approved for migraine treatment. This session during the 2025 AAPP Summit aims to help psychiatric pharmacists understand the risks, benefits, and treatment strategies for implementing CGRP antagonists in the treatment of migraines. #psychpharmacy #aapp #bcpp